Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03913442 · ClinicalTrials.gov registry record · Phase 4
Colchicine for the Treatment of Osteoarthritis of the Knee
A Phase 4 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 120
- Enrollment target
NCT03913442 is a Phase 4 study that has completed, run by NYU Langone Health. The registered enrollment target is 120 participants.
The verdict
NCT03913442, a Phase 4 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 120 participants
- Enrollment target
Study Summary
This prospective, double-blinded, placebo-controlled, randomized trial will enroll 120 SKOA subjects at the NYU Center for Musculoskeletal Care. Patients meeting entry criteria will be randomized 1:1 to treatment with colchicine or placebo daily for 3 months. Subjects will have detailed evaluation of standardized clinical pain outcomes, candidate peripheral blood biomarkers, baseline knee radiographs as well as MSK-US, and a subset will undergo evaluation of their synovial fluid.
Interventions
- DRUG Placebo oral capsule
- DRUG Colchicine 0.8 mg or 0.6 mg orally once daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2019-05-15 |
| Est. Completion | 2024-01-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03913442
The ClinicalTrials.gov registry entry for NCT03913442 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral capsule is the first listed.
NCT03913442 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03913442 about?
NCT03913442 is a clinical study titled "Colchicine for the Treatment of Osteoarthritis of the Knee". This prospective, double-blinded, placebo-controlled, randomized trial will enroll 120 SKOA subjects at the NYU Center for Musculoskeletal Care. Patients meeting entry criteria will be randomized 1:1 to treatment with colchicine or placebo daily for 3 months. Subjects will have detailed evaluation o...
What is the current status of trial NCT03913442?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2019-05-15. Estimated completion is 2024-01-11.
What interventions are being tested in trial NCT03913442?
The interventions under investigation include: Placebo oral capsule (DRUG), Colchicine 0.8 mg or 0.6 mg orally once daily (DRUG).
Who is sponsoring clinical trial NCT03913442?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.